Regulus Therapeutics Inc.
Oligonucleotide therapeutics that modulate microRNA to treat hepatitis B virus infection
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Founded
- 2009
- Latest Form D
- $34.6M, Dec 2021
- Total capital
- $171M
- Federal grants
- $300K
- 1 award
- Rank in peer group#8 of 392
- Private capital raised
- $171M
- 9 Form D · last Dec 2021
- 59 months since last filing
- Federal contracts
- $300K
- 1 award · Health and Human S
- Rank in Biotech#264 of 4373
- Granted patents
- 24
- 16 pending · first 2016
- Rank in peer group#3 of 392
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 9th filing$34.6M
- Private capital raisedForm D · SEC · 8th filing$19.4M
- Federal contractHealth and Human S · Niaid SBIR Phs 2020-1 Topic 084: "antiviral Drugs To Cure Chronic Hepatitis B Virus Infection"$300K
- Private capital raisedForm D · SEC · 7th filing$16.7M
- Private capital raisedForm D · SEC · 6th filing$10M
- Private capital raisedForm D · SEC · 5th filing$5M
- Private capital raisedForm D · SEC · 4th filing$25M
- Private capital raisedForm D · SEC · 3rd filing$20M
- Private capital raisedForm D · SEC · 2nd filing$29.8M
- Private capital raisedForm D · SEC · 1st filing$10M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#8 · top 2%
- Granted patents#3 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Denis DryginResearcherExecutive OfficerLinked by 1 patent
- Alice S. HuangDirectorNamed in SEC Form D filings
- Alice S. HuangDirectorNamed in SEC Form D filings
- Barry E. GreeneDirectorNamed in SEC Form D filings
- B. Lynne ParshallDirectorNamed in SEC Form D filings
- Bruce L.A. CarterDirectorNamed in SEC Form D filings
Show all 29 people
- Christopher AkerExecutive OfficerNamed in SEC Form D filings
- Cris CalsadaExecutive OfficerNamed in SEC Form D filings
- Daniel R. ChevallardExecutive OfficerNamed in SEC Form D filings
- David BaltimoreDirectorNamed in SEC Form D filings
- Douglas E. WilliamsDirectorNamed in SEC Form D filings
- Garry Lynne MenzelExecutive OfficerNamed in SEC Form D filings
- Grantland Lynne BryceExecutive OfficerNamed in SEC Form D filings
- Hugh H. RosenDirectorNamed in SEC Form D filings
- Jake R. NunnDirectorNamed in SEC Form D filings
- Jake R. NunnDirectorNamed in SEC Form D filings
- John E. MaraganoreDirectorNamed in SEC Form D filings
- Joseph HaganExecutive Officer, DirectorNamed in SEC Form D filings
- Kathryn J. CollierDirectorNamed in SEC Form D filings
- Kathryn J. CollierDirectorNamed in SEC Form D filings
- Kleanthis XanthopoulosExecutive Officer, DirectorNamed in SEC Form D filings
- Mark G. FolettaDirectorNamed in SEC Form D filings
- Neil Lynne GibsonExecutive OfficerNamed in SEC Form D filings
- Pascale WitzDirectorNamed in SEC Form D filings
- Simos SimeonidisDirectorNamed in SEC Form D filings
- Stanley CrookeDirectorNamed in SEC Form D filings
- Stelios E. PapadopoulosDirectorNamed in SEC Form D filings
- William H. RastetterDirectorNamed in SEC Form D filings
- William H. RastetterDirectorNamed in SEC Form D filings
What it has protected
USPTO · 24 granted of 40- PendingMethods and Compositions for Treatment of Polycystic Kidney DiseaseUSPTOApplication 19454993
- GrantedMethods and Compositions for Treatment of Polycystic Kidney DiseaseUSPTOUS 12,559,750
- PendingCompositions for Treatment of Polycystic Kidney DiseaseUSPTOApplication 19019923
Show all 40 patent records
- Methods and Compositions for Treatment of Polycystic Kidney DiseaseAug 27, 2026 · Application 19454993Pending
- Methods and Compositions for Treatment of Polycystic Kidney DiseaseFeb 24, 2026 · US 12,559,750Granted
- Compositions for Treatment of Polycystic Kidney DiseaseSep 11, 2025 · Application 19019923Pending
- Methods and Compositions for Avoiding Off-Target EffectsMay 1, 2025 · Application 18693783Pending
- Methods and Compositions for Treatment of Polycystic Kidney DiseaseSep 5, 2024 · Application 18610891Pending
- Galnac Conjugated Modified Oligonucleotides as MIR-122 Inhibitor Having HCV Antiviral Activity with Reduced Hyperbilirubinemia Side-EffectJun 11, 2024 · US 12,005,120Granted
- Compositions for treatment of polycystic kidney diseaseApr 6, 2023 · Application 17814647Pending
- Methods for Oral Delivery of OligonucleotidesMar 31, 2022 · Application 17259366Pending
- MicroRNA Compounds and Methods for Modulating MIR-10B ActivityMar 31, 2022 · Application 17290298Pending
- MicroRNA Compounds and Methods for Modulating MIR-122Apr 15, 2021 · Application 17072919Pending
- Modified Oligonucleotides for Treatment of Polycystic Kidney DiseaseApr 1, 2021 · Application 16948620Pending
- Compounds and Methods for Enhanced Cellular UptakeMar 9, 2021 · US 10,941,400Granted
- Modified Oligonucleotides for Treatment of Polycystic Kidney DiseaseMay 28, 2020 · Application 16463041Pending
- Oligomeric Compounds and Compositions for use in Modulation of Small Non-Coding RNAsMar 10, 2020 · US 10,584,336Granted
- Targeting MicroRNAs for Metabolic DisordersMay 23, 2019 · Application 16140881Pending
- MicroRNA Compounds and Methods for Modulating MIR-122May 16, 2019 · Application 16170312Pending
- Compounds And Methods For Enhanced Cellular UptakeMar 26, 2019 · US 10,240,151Granted
- Methods For Direct Measurement Of Microrna Inhibition And MimicryDec 20, 2018 · Application 15754061Pending
- Microrna Compounds And Methods For Modulating MIR-122Dec 11, 2018 · US 10,150,967Granted
- Targeting Micrornas For Metabolic DisordersNov 27, 2018 · US 10,138,484Granted
- Targeting MicroRNAs for the Treatment of FibrosisOct 25, 2018 · Application 15954059Pending
- Methods for Treatment of Alport SyndromeOct 18, 2018 · Application 15948450Pending
- Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-coding RnasOct 9, 2018 · US 10,093,926Granted
- OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAsSep 11, 2018 · US 10,072,265Granted
- Methods For Use In Modulating MIR-122AJun 12, 2018 · US 9,994,842Granted
- Microrna Compounds And Methods For Modulating MIR-21 ActivityJun 12, 2018 · US 9,994,846Granted
- Targeting Micrornas For The Treatment Of FibrosisMay 15, 2018 · US 9,970,007Granted
- Microrna Compounds And Methods For Modulating MIR-21 ActivityMay 15, 2018 · US 9,970,009Granted
- Methods For Treatment Of Alport SyndromeMay 15, 2018 · US 9,970,011Granted
- Targeting Micrornas For Metabolic DisordersJan 9, 2018 · US 9,862,950Granted
- Microrna Compounds And Methods For Modulating MIR-21 ActivityOct 17, 2017 · US 9,790,496Granted
- Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-coding RnasSep 5, 2017 · US 9,752,146Granted
- Microrna Compounds And Methods For Modulating MIR-21 ActivityJun 27, 2017 · US 9,688,985Granted
- Methods For Treatment Of Alport SyndromeJun 27, 2017 · US 9,688,986Granted
- Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-coding RnasMay 30, 2017 · US 9,663,787Granted
- Microrna Compounds And Methods For Modulating MIR-122Feb 21, 2017 · US 9,574,194Granted
- Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-coding RnasFeb 9, 2017 · Application 15234527Pending
- Targeting Micrornas For The Treatment Of FibrosisJan 31, 2017 · US 9,556,435Granted
- Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-coding RnasDec 27, 2016 · US 9,528,108Granted
- Compounds And Methods For Enhanced Cellular UptakeNov 29, 2016 · US 9,506,030Granted
Related companies, and why
- MIRECULE INCSimilar federal contract value in Biotech · $305K in contracts
- AMYRIS, INC.Similar federal contract value in Biotech · $303K in contracts
- Oncotab, Inc.Similar federal contract value in Biotech · $300K in contracts
- GENECURE LLCSimilar federal contract value in Biotech · $300K in contracts
- Delphi Genomics, LLCSimilar federal contract value in Biotech · $300K in contracts
- Coordination Pharmaceuticals IncSimilar federal contract value in Biotech · $300K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .